HitGen Inc. (SHA:688222)

Market Cap	13.04B
Revenue (ttm)	498.51M
Net Income (ttm)	114.11M
Shares Out	399.44M
EPS (ttm)	0.27
PE Ratio	118.89
Forward PE	138.94
Dividend	0.06 (0.18%)
Ex-Dividend Date	n/a

Volume	14,130,890
Average Volume	25,824,282
Open	32.50
Previous Close	32.83
Day's Range	32.20 - 33.35
52-Week Range	11.83 - 42.98
Beta	0.34
RSI	59.45
Earnings Date	Apr 29, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 483
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688222

Financial Performance

In 2024, HitGen's revenue was 426.99 million, an increase of 14.99% compared to the previous year's 371.32 million. Earnings were 51.36 million, an increase of 26.13%.